1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Caravel Oculus Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery Ophthalmic solution (matching formulation without ascorbic acid), Ascorbic acid ophthalmic solution 5% - Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery | Phase 2 | Recruiting | Caravel Oculus Pty Ltd | 200 | 2026-07-28 | 2026-08-06 |
Corneal Endothelial Cell Loss (1)
Ascorbic Acid (1) · Ophthalmic Solutions (1)
Australia (1)